AN2 Therapeutics, Inc.

NasdaqGS ANTX

AN2 Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.60

AN2 Therapeutics, Inc. Price to Earnings Ratio (P/E) is -0.60 on January 14, 2025, a 93.68% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

AN2 Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.45 on August 16, 2024, which is 24.63% above the current Price to Earnings Ratio (P/E).
AN2 Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -9.79 on February 05, 2024, which is -1,530.39% below the current Price to Earnings Ratio (P/E).
AN2 Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.55.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: ANTX

AN2 Therapeutics, Inc.

CEO	Mr. Eric E. Easom
IPO Date	March 25, 2022
Location	United States
Headquarters	1800 El Camino Real
Employees	41
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Key trends

Past 5 years